Invitrocue Limited announced the signing of its first laboratory agreement in Germany as part of its strategy to make its Onco-PDO™ personalised cancer screening service available to patients and physicians in Germany. Further, the new lab will act as the central reference lab for Onco-PDO™ tests performed throughout Europe. Located in Munich, the laboratory is a shared service provided by Systasy Bioscience GmbH. The agreement will grant Invitrocue access to Systasy's facilities with immediate effect and marks the initiation of the full commercial roll-out of the Onco-PDO™ test in Germany, then gradually to rest of Europe. Invitrocue has already begun a physician education program in collaboration with key cancer centres in Europe and will continue to establish new relationships with leading physicians in addition to ongoing patient education to support its commercialisation plans. The Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a broad panel of chemotherapy drugs to support clinical decision making for individual patients. It is currently available for use by physicians and patients in Asia, where tests are sent to Invitrocue's laboratory in Singapore. The new lab in Germany will also enable Invitrocue to conduct clinical validation studies in new and existing indications for Onco-PDOTM and make Invitrocue's drug toxicology testing services available to commercial partners in Germany. Dr. Giovanna Leoni has been appointed to the role of Head Laboratory Manager. She has extensive experience leading projects with well-known research laboratories in Germany, Italy, UK and the US.